CHF5074 Reduces Biomarkers of Neuroinflammation in Patients with Mild Cognitive Impairment: A 12-Week, Double-Blind, Placebo- Controlled StudyBruno P. Imbimbo, Dottie Norris, Helen Cicirello et al.|Current Alzheimer Research|2013Cited by 78
Pharmacokinetics and Pharmacodynamics of CHF5074 After Short-term Administration in Healthy SubjectsBruno P. Imbimbo, Magdy Shenouda, E. Frigerio et al.|Alzheimer Disease & Associated Disorders|2012Cited by 37
P3‐411: Safety and pharmacokinetics of CHF5074, a novel gamma‐secretase modulator, after single oral administration to healthy humansBruno P. Imbimbo, Joel Ross, Donna Mackintosh et al.|Alzheimer s & Dementia|2010Cited by 1
P1‐269: A 12‐week, double‐blind, placebo‐controlled, dose‐range finding study of CHF5074 in patients with mild cognitive impairmentJoel Ross, Bruno P. Imbimbo, Sanjiv Sharma et al.|Alzheimer s & Dementia|2012Cited by 0
P2‐466: Safety and pharmacokinetics of CHF5074, a novel gamma‐secretase modulator, after multiple oral administrations to healthy humansBruno P. Imbimbo, Magdy Shenouda, Donna Mackintosh et al.|Alzheimer s & Dementia|2011Cited by 0